Creation of virtual worlds from 3D models retrieved from content aware networks based on sketch and image queries

The recent emergence of user generated content requires new content creation tools that will be both easy to learn and easy to use. These new tools should enable the user to construct new high-quality content with minimum effort; it is essential to allow existing multimedia content to be reused as building blocks when creating new content. In this work we present a new tool for automatically constructing virtual worlds with minimum user intervention. Users can create these worlds by drawing a simple sketch, or by using interactively segmented 2D objects from larger images. The system receives as a query the sketch or the segmented image, and uses it to find similar 3D models that are stored in a Content Centric Network. The user selects a suitable model from the retrieved models, and the system uses it to automatically construct a virtual 3D world

Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors

In people with haemophilia, therapeutic clotting agents might be recognised as a foreign protein and induce anti-factor VIII antibodies, known as 'inhibitors'. Drugs insensitive to such antibodies, either recombinant or plasma-derived, are called factor VIII 'by-passing' agents and used for treatment of bleeding in people with inhibitors

Unmasking silent neurotoxicity following developmental exposure to environmental toxicants

AbstractSilent neurotoxicity, a term introduced approximately 25years ago, is defined as a persistent change to the nervous system that does not manifest as overt evidence of toxicity (i.e. it remains clinically unapparent) unless unmasked by experimental or natural processes. Silent neurotoxicants can be challenging for risk assessors, as the multifactorial experiments needed to reveal their effects are seldom conducted, and they are not addressed by current study design guidelines. This topic was the focus of a symposium addressing the interpretation and use of silent neurotoxicity data in human health risk assessments of environmental toxicants at the annual meeting of the Developmental Neurotoxicology Society (previously the Neurobehavioral Teratology Society) on June 30th, 2014. Several factors important to the design and interpretation of studies assessing the potential for silent neurotoxicity were discussed by the panelists and audience members. Silent neurotoxicity was demonstrated to be highly specific to the characteristics of the animals being examined, the unmasking agent tested, and the behavioral endpoint(s) evaluated. Overall, the experimental examples presented highlighted a need to consider common adverse outcomes and common biological targets for chemical and non-chemical stressors, particularly when the exposure and stressors are known to co-occur. Risk assessors could improve the evaluation of silent neurotoxicants in assessments through specific steps from researchers, including experiments to reveal the molecular targets and mechanisms that may result in specific types of silent neurotoxicity, and experiments with complex challenges reminiscent of the human situation

Surface Gap Soliton Ground States for the Nonlinear Schr\"{o}dinger Equation

We consider the nonlinear Schr\"{o}dinger equation $(-\Delta +V(x))u = \Gamma(x) |u|^{p-1}u$, $x\in \R^n$ with $V(x) = V_1(x) \chi_{\{x_1>0\}}(x)+V_2(x) \chi_{\{x_1<0\}}(x)$ and $\Gamma(x) = \Gamma_1(x) \chi_{\{x_1>0\}}(x)+\Gamma_2(x) \chi_{\{x_1<0\}}(x)$ and with $V_1, V_2, \Gamma_1, \Gamma_2$ periodic in each coordinate direction. This problem describes the interface of two periodic media, e.g. photonic crystals. We study the existence of ground state $H^1$ solutions (surface gap soliton ground states) for $0<\min \sigma(-\Delta +V)$. Using a concentration compactness argument, we provide an abstract criterion for the existence based on ground state energies of each periodic problem (with $V\equiv V_1, \Gamma\equiv \Gamma_1$ and $V\equiv V_2, \Gamma\equiv \Gamma_2$) as well as a more practical criterion based on ground states themselves. Examples of interfaces satisfying these criteria are provided. In 1D it is shown that, surprisingly, the criteria can be reduced to conditions on the linear Bloch waves of the operators $-\tfrac{d^2}{dx^2} +V_1(x)$ and $-\tfrac{d^2}{dx^2} +V_2(x)$.Comment: definition of ground and bound states added, assumption (H2) weakened (sign changing nonlinearity is now allowed); 33 pages, 4 figure

Inhibitor development in non-severe haemophilia across Europe

Evidence about inhibitor formation in non-severe haemophilia and the potential role for clotting factor concentrate type is scant. It was the aim of this study to report inhibitor development in non-severe haemophilia patients enrolled in the European Haemophilia Safety Surveillance (EUHASS) study. Inhibitors are reported quarterly and total treated patients annually. Incidence rates and 95 % confidence intervals (95 % CI) were calculated according to diagnosis and concentrate used. Between 1–10–2008 and 31–12–2012, 68 centres reported on 7,969 patients with non-severe haemophilia A and 1,863 patients with non-severe haemophilia B. For haemophilia A, 37 inhibitors occurred in 8,622 treatment years, resulting in an inhibitor rate of 0.43/100 treatment years (95 % CI 0.30–0.59). Inhibitors occurred at a median age of 35 years, after a median of 38 exposure days (EDs; P25-P75: 20–80); with 72 % occurring within the first 50 EDs. In haemophilia B, one inhibitor was detected in 2,149 treatment years, resulting in an inhibitor rate of 0.05/100 years (95% CI 0.001–0.26). This inhibitor developed at the age of six years, after six EDs. The rate of inhibitors appeared similar across recombinant and plasma derived factor VIII (FVIII) concentrates. Rates for individual concentrates could not be calculated at this stage due to low number of events. In conclusion, inhibitors in non-severe haemophilia occur three times more frequently than in previously treated patients with severe haemophilia at a rate of 0.43/100 patient years (haemophilia A) and 0.05/100 years (haemophilia B). Although the majority of inhibitors developed in the first 50 EDs, inhibitor development continued with increasing exposure to FVIII

Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies

This report contains the updated consensus recommendations for optimal hemophilia care produced in 2019 by three Working Groups (WG) on behalf of the European Directorate for Quality of Medicines and Healthcare in the frame of the Kreuth V Initiative. WG1 recommended access to prophylaxis for all patients, the achievement of plasma factor trough levels of at least 3-5% when extended half-life factor VIII (FVIII) and FIX products are used, a personalized treatment regimen, and a choice of chromogenic assays for treatment monitoring. It was also emphasized that innovative therapies should be supervised by hemophilia comprehensive care centers. WG2 recommended mandatory collection of postmarketing data to assure the long-term safety and efficacy of new hemophilia therapies, the establishment of national patient registries including the core data recommended by the European Medicines Agency and the International Society on Thrombosis and Haemostasis, with adequate support under public control, and greater collaboration to facilitate a comprehensive data evaluation throughout Europe. WG3 discussed methodological aspects of hemophilia care in the context of access decisions, particularly for innovative therapies, and recommended that clinical studies should be designed to provide the quality of evidence needed by regulatory authorities, HTA bodies and healthcare providers. The dialogue between all stakeholders in hemophilia care and patient organizations should be fostered to implement these recommendations

Reduced cardiovascular morbidity in patients with hemophilia:results of a 5-year multinational prospective study

Hemophilia is a congenital bleeding disorder caused by low levels of clotting factor VIII or IX. The life expectancy of people with hemophilia (PWH) has increased with the availability of clotting factor concentrates. At the same time, the incidence of cardiovascular disease (CVD) has increased; in retrospective studies, there are conflicting data regarding if, despite this increase, the incidence is still lower than in the general population. We prospectively compared the incidence of CVD in PWH vs the predicted incidence. This prospective, multicenter, observational study included adult PWH (aged &gt;30 years) from The Netherlands and United Kingdom. They were followed up for a 5-year period, and CVD incidence was compared with a predicted event rate based on the QRISK2-2011 CVD risk model. The primary end point was the observed fatal and nonfatal CVD incidence after 5 years compared with the estimated events and in relation to severity of hemophilia. The study included 709 patients, of whom 687 (96.9%) completed 5 years' follow-up or reached an end point. For 108 patients, the QRISK score could not be calculated at inclusion. For the remaining 579, fewer CVD events were observed than predicted: 9 vs 24 (relative risk, 0.38; 95% confidence interval, 0.18-0.80; P 5 .01), corresponding with an absolute risk reduction of 2.4%. Severe hemophilia treated on demand had the highest risk reduction. There was no statistically significant relation between severity of hemophilia and incidence of CVD. In hemophilia, a lower-than-predicted CVD incidence was found, supporting the theory that hemophilia protects against CVD. The study is registered at www.clinicaltrials.gov as #NCT01303900.</p

The antlions of Cyprus: review and new reports (Neuroptera: Myrmeleontidae)

The antlions (Myrmeleontidae) of Cyprus have been poorly studied and only 13 species were known from this biogeographically interesting island. In light of new field research, we provide an updated checklist to the Cypriot antlions, including seven species reported for the first time from the island. Of these, the findings of the Middle Eastern species Distoleon laticollis and Cueta kasyi are particularly noteworthy. The Cypriot antlion fauna appears dominated by widespread Mediterranean elements, with relatively few Middle Eastern and endemic species

Revisiting Vulnerability Analysis in Modern Microprocessors

Abstract-The notion of Architectural Vulnerability Factor (AVF) has been extensively used to evaluate various aspects of design robustness. While AVF has been a very popular way of assessing element resiliency, its calculation requires rigorous and extremely time-consuming experiments. Furthermore, recent radiation studies in 90 nm and 65 nm technology nodes demonstrate that up to 55 percent of Single Event Upsets (SEUs) result in Multiple Bit Upsets (MBUs), and thus the Single Bit Flip (SBF) model employed in computing AVF needs to be reassessed. In this paper, we present a method for calculating the vulnerability of modern microprocessors -using Statistical Fault Injection (SFI)-several orders of magnitude faster than traditional SFI techniques, while also using more realistic fault models which reflect the existence of MBUs. Our method partitions the design into various hierarchical levels and systematically performs incremental fault injections to generate vulnerability estimates. The presented method has been applied on an Intel microprocessor and an Alpha 21264 design, accelerating fault injection by 15Â, on average, and reducing computational cost for investigating the effect of MBUs. Extensive experiments, focusing on the effect of MBUs in modern microprocessors, corroborate that the SBF model employed by current vulnerability estimation tools is not sufficient to accurately capture the increasing effect of MBUs in contemporary processes